College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement

被引:381
作者
Zacny, J
Bigelow, G
Compton, P
Foley, K
Iguchi, M
Sannerud, C
机构
[1] Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA
[2] Johns Hopkins Univ, Sch Med, Behav Biol Res Ctr, Dept Psychiat, Baltimore, MD 21224 USA
[3] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90095 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[5] RAND Corp, Drug Policy Res Ctr, Santa Monica, CA 90401 USA
[6] Drug Enforcement Adm, Off Div Control, Washington, DC 20537 USA
关键词
prescription; opioid; analgesia; dependence; pain; epidemiology; abuse liability;
D O I
10.1016/S0376-8716(03)00003-6
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This position paper from the College on Problems of Drug Dependence addresses the issues related to non-medical use and abuse of prescription opioids. A central theme throughout is the need to strike a balance between risk management strategies to prevent and deter prescription opioid abuse and the need for physicians and patients to have appropriate access to opioid pharmaceuticals for the treatment of pain. The epidemiology of prescription opioid use and abuse is reviewed. Non-medical use and abuse of prescription opioids are on the rise in the United States, illicit use of several widely prescribed opioids has increased disproportionately more than licit use, and the prevalence of prescription opioid abuse appears to be similar to that of heroin and cocaine abuse. There is a paucity of abuse liability testing of prescription opioids, and methods should be developed to fill critical gaps in our knowledge in this area. The role of regulatory agencies in preventing diversion of prescription opioids and identifying potential sources of diversion are discussed. More research is needed to identify those populations most at risk for abusing prescription opioids, and then to develop appropriately targeted prevention programs. Treatment options are discussed; these depend on whether or not an abuser is in pain. Prescription opioid abuse has harmful ramifications for the legitimate and appropriate use of opioids, including stigmatization, opiophobia, and undertreatment of pain. Recommended steps to take include further epidemiological research, laboratory testing of prescription opioids to determine abuse liability, and clinical trials to determine the efficacy of different approaches to the prevention and treatment of prescription opioid abuse. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:215 / 232
页数:18
相关论文
共 69 条
[1]   Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans [J].
Abreu, ME ;
Bigelow, GE ;
Fleisher, L ;
Walsh, SL .
PSYCHOPHARMACOLOGY, 2001, 154 (01) :76-84
[2]  
ANGAROLA RT, 1989, ADV PAIN RES THER, V11, P213
[3]  
[Anonymous], 1998, JAMA, V280, P1936
[4]  
[Anonymous], MOD GUID US CONTR SU
[5]  
[Anonymous], 2002, RES 2001 NAT HOUS SU
[6]  
[Anonymous], 2000, ACH BAL NAT OP CONTR
[7]  
BRADY JV, 1984, NIDA RES MONOGRAPH, V52
[8]   The undertreatment of pain in ambulatory AIDS patients [J].
Breitbart, W ;
Rosenfeld, BD ;
Passik, SD ;
McDonald, MV ;
Thaler, H ;
Portenoy, RK .
PAIN, 1996, 65 (2-3) :243-249
[9]  
CAMI J, 1991, BRIT J ADDICT, V86, P1525
[10]   A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States [J].
Cicero, TJ ;
Adams, EH ;
Geller, A ;
Inciardi, JA ;
Muñoz, A ;
Schnoll, SH ;
Senay, EC ;
Woody, GE .
DRUG AND ALCOHOL DEPENDENCE, 1999, 57 (01) :7-22